USE OF N-(4-AMINO-2-METHYL-QUINOLIN-6-YL)-2-((4-ETHYLPHENOXY)METHYL)BENZAMIDE FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR PROPHYLAXIS OF SYMPTOMS OF INTRINSIC AND/OR EXTRINSIC SKIN AGING AND FOR THE TREATMENT AND/OR PROPHYLAXIS OF DAMAGING EFFECTS OF ULTRAVIOLET RADIATION ON THE SKIN

Abstract

Use of N-(4-amino-2-methylquinoline-6-yl)-2-((4-ethylphenoxy)methypbenzamide for producing cosmetic or dermatological preparations for the treatment and/or prophylaxis of symptoms of intrinsic and/or extrinsic skin aging and for the treatment and/or prophylaxis of damaging effects of ultraviolet radiation on the skin.

Claims

1.-4. (canceled)

5. A method for the treatment and/or prophylaxis of symptoms of intrinsic and/or extrinsic skin aging and for the treatment and prophylaxis of harmful effects of ultraviolet radiation on skin, wherein the method comprises applying to skin in need thereof an effective amount of a cosmetic or dermatological preparation which comprises N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide.

6. The method of claim 5, wherein the preparation comprises from 0.001% to 10% by weight of N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)-benzamide.

7. The method of claim 5, wherein the preparation comprises from 0.01% to 1% by weight of N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)-benzamide.

8. The method of claim 5, wherein dryness, roughness, and development of fine wrinkles are treated or prevented.

9. The method of claim 5, wherein itching is treated or prevented.

10. The method of claim 5, wherein decreased refatting by sebaceous glands is treated or prevented.

11. The method of claim 5, wherein visible vasodilation phenomena are treated or prevented.

12. The method of claim 5, wherein sagging of skin and development of wrinkles are treated or prevented.

13. The method of claim 5, wherein pigmentation disorders are treated or prevented.

14. The method of claim 5, wherein increased susceptibility to mechanical stess is treated or prevented.

15. The method of claim 5, wherein inflammatory skin conditions are treated or prevented.

16. The method of claim 5, wherein the preparation further comprises one or more UV filter substances.

17. The method of claim 16, wherein the preparation comprises from 3% to 20% by weight of one or more UV filter substances, based on a total weight of the preparation.

18. The method of claim 16, wherein the preparation comprises one or more UV filter substances selected from 3-benzylidenecamphor derivatives, 4-aminobenzoic acid derivatives, 2,4,6-tri[anilino-(p-carbo-2′-ethyl-1′-hexyloxy)]-1,3,5 -triazine; esters of benzalmalonic acid; esters of cinnamic acid; derivatives of benzophenone; UV filters bound to polymers; 2-phenylbenzimidazole-5-sulfonic acid and salts thereof; sulfonic acid derivatives of 3-benzylidenecamphor and the sulfonic acid itself.

19. The method of claim 5, wherein the preparation is an emulsion.

20. The method of claim 19, wherein the preparation is an O/W emulsion.

21. The method of claim 19, wherein the preparation is a W/O emulsion.

22. The method of claim 5, wherein the preparation is a hydrodispersion.

23. A cosmetic or dermatological preparation for the treatment and/or prophylaxis of symptoms of intrinsic and/or extrinsic skin aging and for the treatment and/or the harmful effects of ultraviolet radiation on the skin, wherein the preparation comprises a cosmetically or dermatologically effective amount of N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide.

24. The preparation of claim 23, wherein the preparation comprises from 0.01% to 1% by weight of N-(4-amino-2-methylquinolin-6-yl)-2-((4-ethylphenoxy)methyl)benzamide.

Description

EFFICACY TESTS

[0094] For the viability assay, dermal fibroblasts were treated with active substances/active substance combinations in the cell culture medium for 24 h and during this time were provided with BrdU (5-bromodeoxyuridine). The cells take up this synthetic nucleic acid, which is detectable by fluorescence detection, and incorporate it into newly synthesized genetic material during cell division. The fluorescence of the cell monolayer is then measured after 24 h, the intensity of which is ultimately a measure of the cell division rate during treatment with the active substance. This allows conclusions to be drawn about the effect of the individual active substances on cell viability.

[0095] The lipid assay is performed on subcutaneous adipocytes. Cell culture dishes are inoculated with preadipocytes, which undergo differentiation into adipocytes. This is followed by treatment with the active substance for one week, during which the cells synthesize lipids and store them in vesicles. The total amount of lipid as a function of active substance effects is determined at the end of the culture period. This is done by staining the cell monolayer with the lipophilic fluorescent dye AdipoRed, followed by quantification by fluorescence spectroscopy.

[0096] The third assay performed is the LDH (lactate dehydrogenase) cytotoxicity assay. In this assay, the metabolic enzyme LDH is detected in the medium supernatant of the cell monolayer by adding a substrate for the enzyme to the cell culture supernatant. Reaction of the latter produces a color change, which is determined photometrically. The magnitude of the color change correlates here with the amount of LDH in the cell culture supernatant. LDH is however an intracellular enzyme and is able to pass into the medium supernatant of cell cultures only if a cell is damaged, for example as a consequence of toxic substances, and if there is accompanying damage to the cell membrane.

[0097] For all assays, the active substances were present as 1000× stocks dissolved to 10 mg/ml in DMSO and were diluted 1:1000 in the appropriate cell culture medium for use.

Results

[0098]

TABLE-US-00001 Example formulations 1 2 3 4 % by % by % by % by Chemical name weight weight weight weight N-(4-Amino-2-methylquinolin-6-yl)-2- 0.2 0.3 0.5 1 ((4-ethylphenoxy)methyl)benzamide Glyceryl stearate citrate 2.00 2.00 2.00 2.00 Isopropyl palmitate 3.00 2.00 3.00 1.00 Cetyl stearyl alcohol 4.00 3.00 3.00 Cetyl alcohol 4.00 Caprylic acid/capric acid triglyceride 3.00 2.50 2.00 3.00 C12-15 Alkyl benzoate 3.00 2.50 2.00 2.00 Cyclomethicone 1.00 1.00 Dicaprylyl carbonate 2.50 Dimethicone 0.50 Glycerol 5.00 6.00 5.00 6.00 Methylparaben 0.10 Phenoxyethanol 0.40 0.40 0.40 Ethylhexylglycerol 0.30 Glyceryl caprylate 0.3 2-Methyl-1,3-propanediol 0.2 2.00 Carbomer 0.20 0.15 Sodium polyacrylate 0.40 Xanthan gum 0.10 0.15 Acrylates/C10-30 Alkyl Acrylate 0.2 0.10 0.20 Crosspolymer Aluminum starch octenylsuccinate 1.00 Glycyrrhiza inflata root extract 0.03 Vitamin C/ascorbic acid 3.00 Glycine Soja Germ Extract 0.50 Arctium lappa root extract 0.30 Pimpinella anisum fruit extract 4.00 Glycyrrhetinic acid 0.10 Niacinamide 0.20 Magnesium ascorbyl phosphate 0.10 Licorice root extract 0.10 Sea salt 0.05 Bis-Ethylhexyloxyphenol 1.00 Methoxyphenyl Triazine Octocrylene 9.00 4.00 2.00 Butyl Methoxydibenzoylmethane 5.00 3.50 2.00 Ethylhexyl salicylate 5.00 3.00 Sodium hydroxide as as as as required required required required Water to 100 to 100 to 100 to 100